- Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients
-
Li F, Ye J, Sun Y, Lin Y, Wu T, Shao C, Ma Q, Liao X, Feng S, Zhong B
- KMID: 2516343
- Diabetes Metab J.
- 2021 May;45(3):417-429.
- doi: 10.4093/dmj.2020.0039
Background: Excessive delivery of free fatty acids (FFAs) to the liver promotes steatosis and insulin resistance (IR), with IR defined as reduced glucose uptake, glycogen synthesis and anti-lipolysis stimulated by... -
- CITED
-
- Close
- SHARE
-
- Close
- Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible-Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China
-
Zhang R, Shao C, Huo N, Li M, Xu X
- KMID: 2411973
- Gut Liver.
- 2016 May;10(3):446-455.
- doi: 10.5009/gnl15162
BACKGROUND/AIMS: Several studies have demonstrated that serum interferon-γ-inducible-protein-10 (IP-10) levels at baseline and single nucleotide polymorphisms (SNPs) near the IL28B gene were associated with viral response and treatment outcomes. Our... -
- CITED
-
- Close
- SHARE
-
- Close
- Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
-
Liu C, You H, Zeng QL, Wong YJ, Wang B, Grgurevic I, Liu C, Yim HJ, Gou W, Dong B, Ju S, Guo Y, Yu Q, Hirooka M, Enomoto H, Hanafy AS, Cao Z, Dong X, LV J, Kim TH, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Xu C, Dai E, Lan X, Lai C, Liu S, Wang F, Guo Y, Lv J, Zhang L, Wang Y, Xie Q, Shao C, Liu Z, Ravaioli F, Colecchia A, Li J, Teng GJ, Qi X
- KMID: 2563414
- Clin Mol Hepatol.
- 2025 Jan;31(1):105-118.
- doi: 10.3350/cmh.2024.0198
Backgrounds/Aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol... -
- CITED
-
- Close
- SHARE
-
- Close
